Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

A phase 2 study of the KIT inhibitor XL820 in patients with advanced gastrointestinal stromal tumors (GIST) resistant to or intolerant of the tyrosine kinase inhibitors (TKI) imatinib and/or sunitinib

A phase 2 study of the KIT inhibitor XL820 in patients with advanced gastrointestinal stromal tumors (GIST) resistant to or intolerant of the tyrosine kinase inhibitors (TKI) imatinib and/or sunitinib. Connective Tissue Oncology Society Annual Meeting. 2008.


© 2022 President and Fellows of Harvard College
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.